Literature DB >> 31367533

Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice.

Sawsan Rashdan1,2, David E Gerber1,2,3.   

Abstract

Entities:  

Year:  2019        PMID： 31367533      PMCID： PMC6626864          DOI： 10.21037/tlcr.2018.09.15

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  32 in total

1.  Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants.

Authors:  Linda S Elting; Catherine Cooksley; B Nebiyou Bekele; Michael Frumovitz; Elenir B C Avritscher; Charlotte Sun; Diane C Bodurka
Journal:  Cancer       Date:  2006-06-01       Impact factor: 6.860

2.  Under-representation of older adults in cancer registration trials: known problem, little progress.

Authors:  Kevin S Scher; Arti Hurria
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

3.  Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients.

Authors:  Halfdan Sorbye; Per Pfeiffer; Nina Cavalli-Björkman; Camilla Qvortrup; Mari H Holsen; Tore Wentzel-Larsen; Bengt Glimelius
Journal:  Cancer       Date:  2009-10-15       Impact factor: 6.860

4.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials.

Authors:  L F Hutchins; J M Unger; J J Crowley; C A Coltman; K S Albain
Journal:  N Engl J Med       Date:  1999-12-30       Impact factor: 91.245

5.  Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.

Authors:  Corey Langer; Sigui Li; Joan Schiller; William Tester; Bernardo L Rapoport; David H Johnson
Journal:  J Clin Oncol       Date:  2007-02-01       Impact factor: 44.544

Review 6.  Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.

Authors:  Alexis L Franks; Jill E Slansky
Journal:  Anticancer Res       Date:  2012-04       Impact factor: 2.480

7.  Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma.

Authors:  Leo J Schouten; Joost Rutten; Hans A M Huveneers; Albert Twijnstra
Journal:  Cancer       Date:  2002-05-15       Impact factor: 6.860

8.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

9.  Prevalence of poor performance status in lung cancer patients: implications for research.

Authors:  Rogerio C Lilenbaum; John Cashy; Thomas A Hensing; Susan Young; David Cella
Journal:  J Thorac Oncol       Date:  2008-02       Impact factor: 15.609

10.  Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials.

Authors:  Catherine Mengis; Stefan Aebi; Andreas Tobler; Werner Dähler; Martin F Fey
Journal:  J Clin Oncol       Date:  2003-11-01       Impact factor: 44.544
View more
  3 in total

1.  Distribution of pathogenic bacteria in lower respiratory tract infection in lung cancer patients after chemotherapy and analysis of integron resistance genes in respiratory tract isolates of uninfected patients.

Authors:  Haiyan Liu; Bin Liu; Fade Zheng; Xiaoxia Chen; Lingyun Ye; Yayi He
Journal:  J Thorac Dis       Date:  2020-08       Impact factor: 2.895

2.  Consistency of genotyping data from simultaneously collected plasma circulating tumor DNA and tumor-DNA in lung cancer patients.

Authors:  Jiali Zhang; Aoran Dong; Shuzhan Li; Xiubao Ren; Xinwei Zhang
Journal:  J Thorac Dis       Date:  2020-12       Impact factor: 2.895

3.  Treatment and Survival in Advanced Non-Small Cell Lung Cancer, Urothelial, Ovarian, Gastric and Kidney Cancer: A Nationwide Comprehensive Evaluation.

Authors:  Signe Sørup; Bianka Darvalics; Azza Ahmed Khalil; Marianne Nordsmark; Mette Hæe; Frede Donskov; Mads Agerbæk; Leo Russo; Dina Oksen; Emmanuelle Boutmy; Patrice Verpillat; Deirdre Cronin-Fenton
Journal:  Clin Epidemiol       Date:  2021-09-22       Impact factor: 4.790
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.